ADAP earnings call for the period ending June 30, 2020.
News & Analysis: Adaptimmune Therapeutics
Can an early-stage cancer immunotherapy company deliver riches to shareholders?
The biotech continued its winning ways.
Adaptimmune prudently decided to take advantage of its soaring share price to raise capital.
Positive results from a handful of patients treated have bolstered confidence in the company's cell-based approach to cancer treatment.
Big pharma partners could help this cutting-edge cell-therapy company be successful in the future.
ADAP earnings call for the period ending March 31, 2020.
Adaptimmune Therapeutics and OrganiGram Holdings are two penny stocks that may be worth the risk.
These three clinical-stage biotechs are all bargains after last month's marketwide downturn.
These clinical-stage drugmakers could be a steal at current levels.